Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Company’s lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy. The Company has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. The Company is in the process of evaluating additional delivery forms for AR101 for the maintenance phase.
Market Cap:2000M; Shares Outstanding:63.3M; Short Interest: 23.38%; Q3 2019(9/30/19): Cash 195M. Loss 65M
EPS and Sales:
|Date||EPS||% last year||% last quarter|
Total institutions: 167，no change
Shares hold: 51299.9k shares. Reduced 486.9k
shares% hold: 81.04%，decreased by 0.77%